This page is intended to be hidden from public view.
Please do not share it with anyone.
Organizers:
Stuart Johnston (The University of Melbourne), Matthew Faria
Description:
Mathematical models that describe how therapeutic agents interact with biological systems are playing an increasingly vital role in the development of novel drugs. Regulatory agencies, such as the FDA, now recognise the predictive power of accurately developed, calibrated, and validated models in the drug approval pipeline. By combining models and experimental data of pharmacokinetics and pharmacodynamics, we can generate predictions of drug efficacy and safety. However, the majority of research in pharmacometrics focuses on traditional small molecule drugs. Novel therapies are moving beyond this paradigm towards targeted and personalised approaches. Accordingly, we require models capable of describing the more complex and detailed interactions between the therapy and biological system of interest. Moreover, we must ensure that the relevant biological parameters and metrics can be identified and estimated from experiments. In this session, we will hear about recent developments in quantitative pharmacometrics that combine approaches from pharmacokinetic/pharmacodynamic modelling, quantitative systems pharmacology, computational statistics and machine learning to develop quantitative pipelines for establishing the efficacy and safety of next-generation therapeutics.
Diversity Statement:
We have ensured a diverse range of representation of countries across four different continents. We have ensured that we have included researchers from all career stages, and expect near-parity between male and female/non-binary speakers.
Irina Kareva (EMD Serono Research Institute, USA)
"From pre-clinical data to first in human dose projections: a different puzzle every time"
Jae Kyoung Kim (Department of Mathematical Sciences, Korea Advanced Institute of Science and Technology, Republic of Korea)
"Beyond the Michaelis-Menten: Accurate Prediction of Pharmakokinetics and Pharmakodynamics"
Thibault Delobel (Cancer Systems Pharmacology, Institut Curie, France)
" Integrating glioblastoma plasticity into combination treatment design: a quantitative systems pharmacology and machine learning approach"
Stuart Johnston (School of Mathematics and Statistics, The University of Melbourne, Australia)
"Quantifying biological heterogeneity in nano-engineered particle-cell interaction experiments"
Matthew Faria (Department of Biomedical Engineering, The University of Melbourne, Australia)
"Drug delivery kinetics - a path towards rational design"
Yunmin Song (Korea Advanced Institute of Science and Technology, Republic of Korea)
"TBC"
TBC
"(Waiting on final confirmation from two additional speakers, apologies)"
TBC
"Title to be determined."
